Stock DNA
Pharmaceuticals & Biotechnology
USD 10,888 Million (Small Cap)
5.00
NA
0.00%
0.84
-999,999.00%
2.16
Revenue and Profits:
Net Sales:
2,007 Million
(Quarterly Results - Mar 2026)
Net Profit:
13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.64%
0%
27.64%
6 Months
12.49%
0%
12.49%
1 Year
16.81%
0%
16.81%
2 Years
49.52%
0%
49.52%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Solventum Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.50%
EBIT Growth (5y)
-21.35%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
79.30%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
2.16
EV to EBIT
14.45
EV to EBITDA
9.93
EV to Capital Employed
1.63
EV to Sales
1.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
11.28%
ROE (Latest)
39.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 119 Schemes (29.88%)
Foreign Institutions
Held by 338 Foreign Institutions (18.63%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
2,007.00
1,998.00
0.45%
Operating Profit (PBDIT) excl Other Income
252.00
302.00
-16.56%
Interest
62.00
51.00
21.57%
Exceptional Items
-40.00
-103.00
61.17%
Consolidate Net Profit
13.00
63.00
-79.37%
Operating Profit Margin (Excl OI)
61.80%
95.60%
-3.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 0.45% vs -4.68% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -79.37% vs -95.02% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
8,325.00
8,254.00
0.86%
Operating Profit (PBDIT) excl Other Income
1,208.00
1,628.00
-25.80%
Interest
347.00
367.00
-5.45%
Exceptional Items
-169.00
-62.00
-172.58%
Consolidate Net Profit
1,556.00
479.00
224.84%
Operating Profit Margin (Excl OI)
86.40%
133.00%
-4.66%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.86% vs 0.70% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 224.84% vs -64.41% in Dec 2024






